849799-25-3

Upstream product

• 163222-33-1 ezetemibe 
• 795306-55-7 Acetic acid 4-[(2S,3R)-3-[(S)-3-(tert-butyl-dimethyl-silanyloxy)-3-(4-fluoro-phenyl)-propyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenyl ester 
• 795306-57-9 3′-(S)-4-(S)-3-(R)-[3′-t-butyldimethylsilyloxy-3′-(4-fluorophenyl)propyl]-4-(4-hydroxyphenyl)-1-(4-fluorophenyl)azetidin-2-one 
• 795306-53-5 Acetic acid 4-{(2S,3R)-1-(4-fluoro-phenyl)-3-[(S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl]-4-oxo-azetidin-2-yl}-phenyl ester 
• 849799-23-1 Methanesulfonic acid 4-[(2S,3R)-3-[(S)-3-(tert-butyl-dimethyl-silanyloxy)-3-(4-fluoro-phenyl)-propyl]-1-(4-fluoro-phenyl)-4-oxo-azetidin-2-yl]-phenyl ester 

Downstream Products

• 849799-26-4 Methanesulfonic acid 4-{(2S,3S)-1-(4-fluoro-phenyl)-3-[(S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl]-azetidin-2-yl}-phenyl ester 

Relevant academic research and scientific papers

Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption

We have utilized our recently developed in vitro assay to address two key questions in the design of small-molecule cholesterol absorption inhibitors using ezetimibe, the only drug yet approved for the inhibition of cholesterol absorption in the small int

Novel hypocholesterolemic compounds

The present invention relates to novel hypocholesterolemic compounds of formula I useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alo